- Trials with a EudraCT protocol (11,419)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
11,419 result(s) found for: Clinical Protocol.
Displaying page 1 of 571.
EudraCT Number: 2005-004323-18 | Sponsor Protocol Number: 20050130 | Start Date*: 2005-11-24 |
Sponsor Name:Amgen Inc. | ||
Full Title: An Open Label Treatment Extension Study of AMG706 | ||
Medical condition: Subjects With Solid Tumors Previously Treated on a Seperate Amgen Protocol With AMG 706 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) DE (Completed) SE (Completed) HU (Completed) DK (Prematurely Ended) AT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002135-19 | Sponsor Protocol Number: 0164 | Start Date*: 2019-04-11 | |||||||||||
Sponsor Name:Theravance Biopharma Ireland Limited | |||||||||||||
Full Title: A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis (UC) | |||||||||||||
Medical condition: Moderately-to-severely active Ulcerative Colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Completed) PT (Prematurely Ended) SK (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001736-95 | Sponsor Protocol Number: ACCORD-2-001,Sub002,003,006 | Start Date*: 2020-04-28 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients | |||||||||||||
Medical condition: COVID 19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000607-42 | Sponsor Protocol Number: KN-1/06 | Start Date*: 2006-02-20 |
Sponsor Name:Institute for clinical and experimental Medicine | ||
Full Title: Treatment of borderline changesin protocol biopsy 3 months after renal transplantation | ||
Medical condition: Patients with transplanted kidney and stabilised graft function | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002457-29 | Sponsor Protocol Number: B9991046 | Start Date*: 2021-12-23 |
Sponsor Name:Pfizer Inc. | ||
Full Title: AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES | ||
Medical condition: This Master Protocol for Avelumab Continuation Sub-Studies has been designed to accommodate continued access to study intervention, safety follow-up, and when applicable, overall survival follow up... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) BE (Ongoing) IT (Ongoing) HU (Ongoing) PL (Ongoing) DK (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002392-41 | Sponsor Protocol Number: Z102-009 | Start Date*: 2012-03-28 | |||||||||||
Sponsor Name:Zalicus, Inc. | |||||||||||||
Full Title: A PHASE II, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER, RANDOMIZED, LONG TERM SAFETY TRIAL OF Z102 AND PREDNISONE (5 MG OR 7.5 MG) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS | |||||||||||||
Medical condition: Treatment of patients with moderate to severe rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002205-22 | Sponsor Protocol Number: IM014029 | Start Date*: 2020-05-01 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: "A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögr... | |||||||||||||||||||||||
Medical condition: SLE Sub-protocol: Systemic Lupus Erythematosus pSS Sub-protocol: Primary Sjögren’s Syndrome RA Sub-protocol: Rheumatoid Arthritis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) ES (Completed) PL (Completed) NL (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003153-15 | Sponsor Protocol Number: GS-US-419-4016 | Start Date*: 2017-08-01 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease | |||||||||||||
Medical condition: Perianal Fistulizing Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) DE (Completed) PL (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003739-30 | Sponsor Protocol Number: AMLSG 05-04 | Start Date*: 2005-11-02 |
Sponsor Name:Universitätsklinikum Ulm / University Clinical Center Ulm | ||
Full Title: Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM] | ||
Medical condition: primary refractory patients with acute myeloid leukemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002093-30 | Sponsor Protocol Number: NO17754 | Start Date*: 2005-12-22 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon α-2a (PEG-I... | ||
Medical condition: Treatment of CML, MM or RCC. | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000541-41 | Sponsor Protocol Number: N/A | Start Date*: 2021-04-22 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial | |||||||||||||
Medical condition: SARS-CoV-2- infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) BE (Ongoing) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Ongoing) AT (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002195-13 | Sponsor Protocol Number: CNTO1959CRD3001 | Start Date*: 2019-06-05 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Seve... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Restarted) BE (Ongoing) AT (Completed) LT (Restarted) CZ (Ongoing) SK (Ongoing) NL (Ongoing) LV (Ongoing) ES (Ongoing) PL (Ongoing) GR (Temporarily Halted) PT (Restarted) HR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001093-11 | Sponsor Protocol Number: A6181030 | Start Date*: 2004-12-24 | |||||||||||
Sponsor Name:Pfizer Global Research and Development | |||||||||||||
Full Title: A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol | |||||||||||||
Medical condition: This is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) NL (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001860-27 | Sponsor Protocol Number: UoL001542 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment | |||||||||||||
Medical condition: Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2024-000001-33 | Sponsor Protocol Number: C4591048 | Start Date*: 2024-02-07 | |||||||||||||||||||||
Sponsor Name:BioNTech SE | |||||||||||||||||||||||
Full Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Children | |||||||||||||||||||||||
Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002557-19 | Sponsor Protocol Number: MT-1303-E14 | Start Date*: 2014-11-27 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC) | |||||||||||||
Full Title: A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects with Moderate to Severe Active Crohn’s Disease who have Completed the MT-1303-E13 Study | |||||||||||||
Medical condition: Subjects with moderate to severe crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SK (Completed) NL (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002900-10 | Sponsor Protocol Number: APD001 | Start Date*: 2016-01-29 |
Sponsor Name:UCB Celltech, UK Registered Branch of UCB Pharma SA | ||
Full Title: AN OPEN-LABEL EXPLORATORY STUDY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS) | ||
Medical condition: Activated PI3K delta Syndrome (APDS) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) DE (Completed) ES (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005217-24 | Sponsor Protocol Number: GS-US-326-1100 | Start Date*: 2015-11-19 | |||||||||||
Sponsor Name:Gilead Sciences, Inc | |||||||||||||
Full Title: A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulce... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) GB (Completed) AT (Prematurely Ended) DE (Completed) BE (Completed) NL (Prematurely Ended) LV (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IE (Prematurely Ended) IS (Prematurely Ended) HR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001225-43 | Sponsor Protocol Number: IB-0121 | Start Date*: 2021-06-14 |
Sponsor Name:Instituto Bernabeu | ||
Full Title: Dual Stim comparison of triggers for the second egg collection: Is there any advantage using 3 different methods of trigger for the second egg collection in Dual Stim cycles in predicted low respon... | ||
Medical condition: Patients with predictive indicators of low ovarian response (according to Poseidon criteria) and who undergo double ovarian stimulation (Dual Stim). | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000613-16 | Sponsor Protocol Number: CATCOVID-v1.2 | Start Date*: 2021-11-26 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial | ||
Medical condition: Patients with acute SARS-CoV-2 infection, proven by a positive SARS-CoV-2 PCR test. The health status of the patients at inclusion in the clinical trial is rated 5 - 6 according to the WHO scale (s... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.